Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neoplasm
100%
Endoscopic Submucosal Dissection
92%
Surgery
53%
Malignant Neoplasm
46%
Stomach Cancer
42%
Disease
42%
Esophageal Cancer
35%
Ulcerative Colitis
34%
Endoscopic Surgery
33%
Endoscopy
32%
Adverse Event
32%
Atrial Fibrillation
28%
Esophagectomy
26%
Esophageal Squamous Cell Carcinoma
25%
Overall Survival
24%
Sepsis
24%
Recurrent Disease
23%
Diagnosis
22%
Computer Assisted Tomography
22%
Bleeding
21%
COVID-19
20%
Epithelioma
20%
Infection
20%
Quality of Life
20%
Randomized Controlled Trial
19%
Patient with Ulcerative Colitis
18%
Adenocarcinoma
18%
Colonoscopy
18%
Retrospective Study
18%
Nivolumab
18%
Odds Ratio
17%
Symptom
17%
Endoscopic Mucosal Resection
17%
Injury
16%
Observational Study
16%
Biological Marker
15%
Immune Checkpoint Inhibitor
15%
Cohort Analysis
15%
Colon
15%
Lung Cancer
15%
Peritoneal Dialysis
14%
Meta-Analysis
13%
Systematic Review
13%
Non Small Cell Lung Cancer
13%
Next Generation Sequencing
13%
Gene Mutation
13%
Inflammatory Bowel Disease
13%
Metastatic Carcinoma
12%
Hazard Ratio
12%
Duodenum Tumor
12%
Diseases
12%
Capsule Endoscopy
12%
Catheter Ablation
12%
Pancreas Cancer
12%
Adenoma
12%
Medicine
11%
Crohn's Disease
11%
Retrospective Cohort Study
11%
Clinical Trial
11%
Endoscope
10%
Breast Cancer
10%
Lymph Node Metastasis
10%
Allogeneic Hematopoietic Stem Cell Transplantation
10%
Gastrectomy
10%
Health Status
10%
Colorectal Cancer
10%
Prospective Cohort Study
10%
Carcinoma
10%
Cancer
10%
Epidermal Growth Factor Receptor
9%
Chemoradiotherapy
9%
Dysplasia
9%
Biopsy
9%
T Cell
9%
Prognostic Factor
9%
Survival Rate
9%
Intensive Care Unit
9%
Cross Sectional Study
9%
Squamous Cell Carcinoma
9%
Oncology
9%
Sentinel Node
9%
Progression Free Survival
9%
Electrocardiogram
8%
Knee
8%
Kidney Function
8%
Hemodialysis
8%
Multivariate Analysis
8%
Cisplatin
8%
Solid Malignant Neoplasm
8%
Colorectal Tumor
8%
Lung Adenocarcinoma
8%
Health Care Cost
8%
Duodenum
8%
Gastrointestinal Endoscopy
8%
Prevalence
8%
Kampo
8%
Placebo
7%
Recurrence Free Survival
7%
Outpatient
7%
Prostate Cancer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
36%
Disease
34%
Chemotherapy
33%
Ulcerative Colitis
31%
Stomach Cancer
31%
Malignant Neoplasm
30%
Remission
29%
Adverse Event
23%
Cohort Study
22%
Atrial Fibrillation
21%
Infection
20%
Sepsis
18%
Overall Survival
17%
Mouse
17%
Hemodialysis
17%
Inflammation
16%
Crohn's Disease
16%
Lung Cancer
15%
Esophagus Cancer
15%
Non Small Cell Lung Cancer
15%
Symptom
14%
Biological Marker
14%
Coronavirinae
13%
Fibrinogen
13%
Observational Study
12%
Randomized Controlled Trial
12%
Recurrent Disease
12%
Pharmacokinetics
12%
Helicobacter Pylori
12%
Pancreas Cancer
11%
Inflammatory Bowel Disease
11%
Epidermal Growth Factor Receptor
11%
Combination Therapy
10%
Placebo
10%
Chronic Kidney Failure
10%
Acute Lung Injury
10%
Esophageal Squamous Cell Carcinoma
10%
Heart Failure
10%
Adult Respiratory Distress Syndrome
9%
Infliximab
9%
Progression Free Survival
9%
Prospective Cohort Study
9%
Cisplatin
9%
Cardiovascular Disease
8%
Clinical Trial
8%
Tumor Necrosis Factor
8%
Diseases
8%
Chemoradiation Therapy
8%
Breast Cancer
8%
Survival Rate
7%
Bleeding
7%
Renin
7%
Aminosalicylic Acid
7%
Fluorouracil
7%
Flurbiprofen
7%
Nivolumab
7%
Health Status
7%
Kampo Medicine (Drug)
7%
Disseminated Intravascular Clotting
6%
Syndrome
6%
Injury
6%
Ulcer
6%
Hospital Mortality
6%
Rat Model
6%
C Reactive Protein
6%
Receptor
6%
Cytokine
6%
Prevalence
6%
Retrospective Study
6%
Adenocarcinoma
6%
Peritonitis
6%
Monotherapy
6%
Creatinine
6%
Liposome
6%
Protein Tyrosine Kinase Inhibitor
5%
Phase II Trials
5%
Hemostatic Agent
5%
Anticarcinogen
5%
Alendronic Acid
5%
Systemic Inflammatory Response Syndrome
5%
Thrombocytopenia
5%
Anticoagulant Agent
5%
Immune Checkpoint Inhibitor
5%
End Stage Renal Disease
5%
Irinotecan
5%
SARS Coronavirus
5%
Adenosine Diphosphate
5%
Sulfotransferase
5%
Angiotensin
5%
Recurrence Free Survival
5%
Keyphrases
Endoscopic Submucosal Dissection
33%
Japan
26%
Confidence Interval
22%
Ulcerative Colitis
19%
Japanese Patients
13%
Tumor
13%
Superficial Duodenal Epithelial Tumor
13%
Odds Ratio
13%
Endoscopic Resection
12%
Esophageal Cancer
11%
Chemotherapy
10%
Gastric Cancer
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
9%
Overall Survival
9%
Nivolumab
9%
Inflammatory Bowel Disease
8%
Meta-analysis
7%
Immune Checkpoint Inhibitors
7%
Esophageal Squamous Cell Carcinoma
7%
Adverse Events
7%
Sepsis
7%
Early Gastric Cancer
7%
Non-small Cell Lung Cancer (NSCLC)
7%
Mucosal Defects
6%
Thrombocytopenia
6%
Colorectal Cancer
6%
Clinical Outcomes
6%
Retrospective Cohort Study
6%
Hazard Ratio
6%
Multicenter Cohort Study
6%
Red Dichromatic Imaging
6%
En Bloc Resection
6%
Endoscopic mucosal Resection
6%
Neoplasia
6%
COVID-19
6%
Endoscopic Surgery
6%
Endoscopy
6%
T Cells
6%
Clinical Characteristics
6%
Phase II Trial
5%
Bleeding
5%
Albumin
5%
Advanced Gastric Cancer
5%
Ulcerative Colitis Patient
5%
Clinical Utility
5%
Multicenter Retrospective Study
5%
Systematic Meta-analysis
5%
Duodenal Endoscopic Submucosal Dissection
5%
Randomized Controlled Trial
5%
Severe Sepsis
5%
Human Herpesvirus 6 (HHV-6)
5%
Gastric Endoscopic Submucosal Dissection
5%
Comprehensive Genomic Profiling
5%
Risk Factors
5%
Artificial Intelligence
5%